Table 1.
Randomized clinical trials evaluating temporary ovarian suppression with GnRHa during chemotherapy as a strategy for ovarian function preservation in premenopausal women with breast cancer. Abbreviations: CT chemotherapy, DFS disease-free survival, E2 estradiol, FSH follicle-stimulating hormone, GnRHa gonadotropin-releasing hormone agonist, POI premature ovarian insufficiency, PM post-menopausal, OS overall survival
| Authors | POI definition | Timing POI evaluation (months) | Treatment regimen | No. patients | Median age (years) (GnRHa vs. control) | POI rate (GnRHa vs. control) | Pregnancies |
|---|---|---|---|---|---|---|---|
| Li et al. [9] | Amenorrhea | 12 | CT + / − goserelin | 63 | 40 vs. 39 | 32.1% vs. 53.1% (p = 0.027) | NA |
| Badawy et al. [11] | Amenorrhea and no resumption of ovulation | 8 | CT + / − goserelin | 78 | 30 vs. 29.2 | 11.4% vs. 66.6% (p < 0.001) | NA |
| Sverrisdottir et al. [10] | Amenorrhea | Up to 36 | CT + / − goserelin (+ / − tamoxifen) (+ − /tamoxifen) | 94 | 45 vs. 45–46 | 64% (93%) vs. 90% (87%) (p = 0.006) | NA |
| Gerber et al. [12] | Amenorrhea | 6 | CT + / − goserelin | 60 | 35 vs. 38.5 | 30% vs. 43.3% (p = 0.142) | 1 vs. 1 |
| Sun et al. [13] | Amenorrhea | 12 | CT + / − goserelin | 21 | 38 vs. 37 | 27.3% vs. 50.0% (p = 0.039) | NA |
| Lambertini et al. [20] | Amenorrhea and PM levels of FSH and E2 | 12 | CT + / − triptorelin | 281 |
39 vs. 39 39 |
8.9% vs. 25.9% (p < 0.001) | 8 vs. 3 (p = 0.20) |
| Munster et al. [14] | Amenorrhea | 24 | CT + / − triptorelin | 49 | 39 vs. 38 | 15% vs. 14% (p = 0.32) | 0 vs. 2 |
| Elgindy et al. [15] | Amenorrhea | 12 | CT + / − triptorelin (± GnRHa antagonist) | 100 | 33 vs. 32 | 20%/16% vs. 20%/20% (p = 1.00/p = 0.71) | 2 vs. 1 |
| Song et al. [16] | Amenorrhea and PM levels of FSH and E2 | 12 | CT + / − leuprolide acetate | 183 | 40.3 vs. 42.1 | 16.9% vs. 28.7% (p < 0.01) | NA |
| Jiang et al. [17] | Amenorrhea | NA | CT + / − triptorelin | 32 | NA | 10.0% vs. 45.5% (p = 0.05) | NA |
| Karimi-Zarchi et al. [18] | Amenorrhea | 6 | CT + / − triptorelin | 42 | 37 | 9.5% vs. 66.7% (p < 0.001) | NA |
| Moore et al. [19] | Amenorrhea and PM levels of FSH | 24 | CT + / − goserelin | 218 | 37.6 vs. 38.7 | 8% vs. 22% (p = 0.04) | 22 vs. 12 (p = 0.03) |
| Leonard et al. [21] | Amenorrhea and PM levels of FSH | 12–24 | CT + / − goserelin | 221 | 37.9 vs. 38.8 | 18.5% vs. 34.8% (p = 0.048) | 7 vs. 5 |
| Zhang et al. [22] | Amenorrhea and PM levels of FSH and E2 | 36–72 | CT + / − goserelin | 216 | 37.5 vs. 39 | 23.1% vs. 22.8% (p = 0.969) | NA |
| Zong et al. [23] | AMH < 0.5 ng/mL | 12 | CT + / − goserelin or leuprolelin | 301 | 40.6 vs. 40.2 | 10.3% vs. 44.5% (p =) | NA |